Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Open Access

Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression

View Full Paper
Ask AI
Bookmark
Share

Authors

BTBala TheivanthiranUniversity of North Carolina at Chapel HillNYNagendra Sastry YarlaEmory UniversityKVKaylee VillarealDuke Medical Center

Discussion

Loading...

Member takes

Implication

Analysis reveals nlrp3 amplification reduces mhc class i levels in melanoma and gastroesophageal cancers, indicating a potential therapeutic target.

Key Points

  • NLRP3 amplification promotes immunotherapy resistance by reducing MHC class I levels in tumors.
  • Data show elevated NLRP3 signaling activity correlates with checkpoint inhibitor resistance in melanoma and GE adenocarcinoma.
  • Pre-clinical models confirm that inhibiting NLRP3 enhances MHC class I surface expression, suggesting a new treatment strategy.
  • The tumor NLRP3 inflammasome may serve as a biomarker and potential therapeutic target in overcoming cancer resistance.

Cite This Study

Theivanthiran et al. (2025) studied this question.

synapsesocial.com/papers/68e70da790569dd607ee59e3https://doi.org/10.1101/2025.10.06.25337175
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of a prognostic pyroptosis-related gene signature for head and neck squamous cell carcinoma patient2022 · 19 citations
  2. 2Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations2019 · 132 citations
  3. 3The Ins and Outs of STAT1 Nuclear Transport2003 · 10 citations
  4. 4Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling2021 · 79 citations